Next, adenoviruses carrying EP300-AS1 inhibited NSCLC growth in a dose-dependent manner both in vitro and in vivo, suggesting that EP300-AS1 had therapeutic potential for NSCLC. This evidence concerns the gene EP300 and non-small cell lung carcinoma.